Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient
Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment
Saved in:
Published in | Lung cancer (Amsterdam, Netherlands) Vol. 95; pp. 35 - 38 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier Ireland Ltd
01.05.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment |
---|---|
Bibliography: | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
ISSN: | 0169-5002 1872-8332 |
DOI: | 10.1016/j.lungcan.2016.02.015 |